GLP-1s and Libido: What the Research Says About Sex Drive, Erections, and Hormones

Few people ask their prescriber about it. Plenty of them search for it at midnight. Does a GLP-1 change your sex drive?

The honest answer has two halves that point in opposite directions. Over months, losing a meaningful amount of weight tends to help sexual function, with the clearest data in men with obesity and erectile dysfunction. In the short run, the early weeks of semaglutide or tirzepatide can bring nausea, tiredness, and a very low food intake, and none of those do much for desire.

On top of that sits a 2024 database study linking semaglutide to more erectile dysfunction diagnoses, which got wide press coverage and is easy to misread. This article goes through what the trials and observational studies actually show for men and for women, how testosterone fits in, and what is still unknown.

Do GLP-1 medicines lower sex drive?

Not as a listed side effect, but early weeks can be flat

GLP-1 medicines are not known to lower sex drive as a direct effect. The Wegovy and Zepbound prescribing information list nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue among the common adverse reactions, and decreased libido is not on either list. The STEP 1 trial of semaglutide 2.4 mg (Wilding, New England Journal of Medicine, 2021) and the SURMOUNT-1 trial of tirzepatide (Jastreboff, New England Journal of Medicine, 2022) together enrolled about 4,500 adults and did not flag sexual side effects above placebo.

That does not mean nobody notices a change. Obesity trials were not designed to measure sexual function, and people rarely volunteer the subject to a trial nurse. Online forums are full of reports of a quieter sex drive during the first months, mixed with just as many reports of more confidence and more interest after weight comes off. Both experiences fit the research once the timeline is separated into the early escalation phase and the longer weight-loss phase.

How common is erectile dysfunction before any medicine is involved?

Very common, and tied to metabolic health

Erectile dysfunction affects about half of men in midlife. The Massachusetts Male Aging Study surveyed 1,290 men aged 40 to 70 and found 52 percent reported some degree of erectile dysfunction: 17.2 percent minimal, 25.2 percent moderate, and 9.6 percent complete (Feldman, Journal of Urology, 1994). Rates of complete dysfunction roughly tripled between age 40 and age 70.

Erectile dysfunction shares its risk factors with the conditions GLP-1 medicines are prescribed for. Obesity, type 2 diabetes, high blood pressure, and poor cardiovascular fitness all damage the blood vessel lining that erections depend on. The men most likely to start a GLP-1 are therefore already the men most likely to have, or soon develop, erectile problems. That background rate matters a great deal when reading any study that links a GLP-1 to an ED diagnosis.

Does losing weight improve erectile function?

The best randomized evidence says yes

Losing weight improves erectile function in many men with obesity. Esposito and colleagues randomized 110 men with obesity and erectile dysfunction, none with diabetes or high blood pressure, to either an intensive programme of calorie reduction and exercise or general health advice (JAMA, 2004). After two years, average BMI in the programme group fell from about 36.9 to 31.2, while the control group barely moved.

Erectile function followed the weight. Seventeen of 55 men in the programme, 31 percent, reached a normal score on the IIEF-5 questionnaire, compared with 3 of 55 controls, or 5.5 percent. Lower BMI and more physical activity were each independently linked to better scores. The trial did not use a GLP-1, but it shows what a loss of around 15 percent of body weight can do, which is close to the average in the semaglutide 2.4 mg trials.

Does a GLP-1 raise testosterone?

Indirectly, through fat loss

A GLP-1 can raise testosterone indirectly in men whose levels are held down by excess weight. Fat tissue converts testosterone to estradiol through the aromatase enzyme, and insulin resistance lowers sex hormone binding globulin and blunts the brain signals that drive the testes. Corona and colleagues pooled weight-loss studies and found total testosterone rose by an average of 2.87 nmol/L after low-calorie diets and 8.73 nmol/L after bariatric surgery (European Journal of Endocrinology, 2013). The larger the weight loss, the larger the rise.

Testosterone is only one input to libido and erections, and a modest rise does not guarantee a noticeable change. A GLP-1 is not a testosterone treatment either. Men with low testosterone from pituitary disease, testicular problems, opioid use, or other causes will not see their levels fixed by weight loss, and a symptom like falling morning erections deserves a proper hormone workup rather than a wait-and-see approach.

What did the 2024 semaglutide erectile dysfunction study find?

A signal worth watching, not proof of harm

The 2024 study found more erectile dysfunction diagnoses in non-diabetic men prescribed semaglutide than in similar men who were not. Able and colleagues used the TriNetX health records network to match men with obesity on semaglutide against controls, and reported new ED diagnoses in 1.47 percent versus 0.32 percent (International Journal of Impotence Research, 2024). Diagnoses of testosterone deficiency were also higher in the semaglutide group.

A records study like this one can show an association but not a cause. Men who start a prescription weight-loss drug have more appointments, more blood tests, and more conversations about their health, which raises the chance that an existing problem gets written down. Matching cannot fully adjust for differences in weight trajectory, fitness, alcohol use, or mood. The absolute numbers were also small, and both rates sit far below the roughly 50 percent background prevalence seen in population surveys, which says as much about how rarely ED gets coded as about how often it occurs.

The finding still deserves attention. It is the kind of signal that should prompt a properly designed trial using validated questionnaires, and it is a good reason for men on a GLP-1 to mention any change in erectile function early rather than assume it is unrelated.

Why might libido dip in the first weeks on a GLP-1?

Low fuel, low mood, low energy

An early libido dip on a GLP-1 most plausibly comes from eating far less and feeling unwell during dose escalation. In STEP 1, 44.2 percent of people on semaglutide reported nausea at some point, mostly during the first 20 weeks, and fatigue was more common than on placebo. Many people on a new GLP-1 eat 30 to 40 percent fewer calories than before. Sharp energy deficits are known to suppress reproductive hormones in both sexes, which is the same pattern seen in athletes who under-fuel.

A second idea involves the brain's reward system. GLP-1 receptors sit in dopamine-rich areas that handle wanting and pleasure, which is part of why GLP-1 medicines quiet food noise and, in some studies, reduce alcohol intake. Vestlund and Jerlhag reported that a GLP-1 receptor agonist reduced sexual interaction in male mice (Psychoneuroendocrinology, 2020). Whether anything similar happens in people at clinical doses is unknown, and the human trial data so far do not show it.

The practical upshot is that a flat few weeks during escalation is common and usually temporary. Eating enough protein, keeping meals regular on the days after an injection, sleeping well, and staying active all support energy and hormone balance. A dip that persists once the dose is stable and eating has settled is worth raising with a prescriber.

How do GLP-1 medicines affect women's sexual health?

Less data, several moving parts

Direct research on GLP-1 medicines and female sexual function is limited, but weight-loss studies point in a broadly positive direction. In a Look AHEAD ancillary study, Wing and colleagues followed women with type 2 diabetes and found that those in the intensive lifestyle arm who reported sexual dysfunction at the start were more likely to report improvement after one year (Diabetes Care, 2013). Body image, mood, and energy each feed into desire and arousal, and all three can shift with weight loss.

Women with polycystic ovary syndrome have a particular stake here. PCOS raises androgen levels and is closely tied to insulin resistance, and weight loss of 5 to 10 percent can restore more regular cycles in many women with PCOS. Fertility can change faster than expected, which has led to reports of unplanned pregnancies on GLP-1 medicines.

Contraception deserves a specific mention. The Zepbound label advises women using oral contraceptives to switch to a non-oral method, or add a barrier method, for four weeks after starting tirzepatide and after each dose increase, because delayed stomach emptying can reduce absorption. Vomiting on any GLP-1 can have the same effect on the pill. The Wegovy label advises stopping semaglutide at least two months before a planned pregnancy, and anyone planning a pregnancy should talk through timing with their prescriber.

What can help protect sexual health while on a GLP-1?

Mostly the basics that support the whole protocol

Protecting sexual health on a GLP-1 mostly means avoiding the conditions that suppress hormones and energy: too little food, too little protein, poor sleep, and a sedentary routine. None of the steps below has been tested as a formal intervention in a GLP-1 trial. Each one targets a mechanism with good evidence behind it.

Could a lower dose GLP-1 protocol be gentler on libido?

A reasonable idea that nobody has tested

A lower dose GLP-1 protocol might be gentler on libido, but no study has measured it. The reasoning is indirect. The factors that seem to drive short-term dips, including nausea, fatigue, and very low food intake, are all more common at higher doses and during fast escalation. A smaller, steadier dose could plausibly reduce them.

The trade-off is that the longer-term benefits to erectile function and testosterone seem to scale with the amount of weight lost, and a lower dose usually means slower or smaller loss. For someone whose main goal is metabolic health with fewer side effects, that may be a fair exchange. Any decision about dose belongs with a prescriber who knows the full picture, including other medicines and hormone levels.

When should a change in sexual function be checked by a doctor?

Sooner rather than later

A change in sexual function should be checked by a doctor if it lasts more than a few weeks after the dose has stabilised, or if it appears suddenly. New erectile dysfunction can be an early warning of cardiovascular disease, often showing up several years before chest pain or a heart attack, because the penile arteries are smaller than the coronary arteries. That alone makes it worth reporting.

Loss of morning erections, low energy, reduced body hair, or breast tenderness in men can point to low testosterone and warrant a morning blood test. In women, new pain with sex, vaginal dryness, or cycle changes deserve a review. Low mood, loss of interest in things beyond sex, or thoughts of self-harm need prompt attention from a healthcare provider.

Frequently Asked Questions